Notice2026-07769
Government-Owned Inventions; Availability for Licensing
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
April 22, 2026
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is giving notice of the invention listed below, which is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Full Text
<html>
<head>
<title>Federal Register, Volume 91 Issue 77 (Wednesday, April 22, 2026)</title>
</head>
<body><pre>
[Federal Register Volume 91, Number 77 (Wednesday, April 22, 2026)]
[Notices]
[Pages 21508-21509]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2026-07769]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Institute of Allergy and Infectious Diseases
(NIAID), an institute of the National Institutes of Health (NIH),
Department of Health and Human Services (HHS), is giving notice of the
invention listed below, which is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Inquiries related to this licensing
opportunity should be directed to: Brian Bailey at 240-669-5128, or
<a href="/cdn-cgi/l/email-protection#b9dbdbd8d0d5dcc0f9d4d8d0d597d7d0d197ded6cf"><span class="__cf_email__" data-cfemail="254747444c49405c6548444c490b4b4c4d0b424a53">[email protected]</span></a>. Licensing information may be obtained by
communicating with the Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852: tel. 301-496-2644. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished information related to the invention.
SUPPLEMENTARY INFORMATION: Technology descriptions follows:
Neutralizing Monoclonal Antibodies Against West Nile Virus.
Description of Technology
West Nile virus (WNV) is a mosquito-borne flavivirus that can cause
fever and, in some cases, severe neurologic disease. There is no
approved human vaccine or specific antiviral treatment for WNV.
Researchers at NIAID's Vaccine Research Center (VRC), working with
collaborators at Sheba Medical Center under the PREMISE program,
identified five new human monoclonal antibodies that potently
neutralize WNV. These antibodies bind the viral envelope (E) protein,
with data indicating recognition of E dimers or quaternary epitopes on
the virion.
The invention includes compositions comprising the antibodies alone
or in combination, nucleic acids encoding them, vectors and host cells
for production, and methods for preventing, treating, or detecting WNV
infection. The antibodies may be formulated for therapeutic
administration, including emergency-use settings, and may also support
diagnostic and research applications.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications
<bullet> Prevention or treatment antibodies for WNV, including use
alone or in combination.
<bullet> Antibodies that strongly target the WNV E protein.
<bullet> Potential treatments for WNV outbreak response and
prevention in high-risk populations.
<bullet> Genetic and cell-engineering tools for antibody production
and product development.
<bullet> Antibodies for WNV detection, surveillance, and research
tests.
<bullet> Potential intravenous treatments for patients with WNV.
Competitive Advantages
<bullet> Shown to strongly neutralize WNV at low concentrations in
laboratory cell-based studies.
<bullet> Novel antibodies with distinct molecular features not
previously reported in scientific literature.
<bullet> Human monoclonal antibodies targeting E dimer or
quaternary epitopes on the WNV virion.
<bullet> Potential applications in WNV treatment, diagnostics, and
surveillance.
<bullet> Collaboration may help speed development to support WNV
outbreak response.
Development Stage
<bullet> Pre-Clinical
Inventors: Dr. Daniel Douek, Dr. Chaim Schramm, Dr. Ananda
Chowdhury, Dr. Parker Dabbs, Dr. Lu Wang, Dr. Sarah Smith, Dr. Leonid
Serebryannyy, Dr. Theodore C. Pierson, Dr. Kimberly Dowd, Dr. Katherine
Burgomaster, Dr. Laura Vanblargan, Dr. David Gordon, and Dr. Yuxiang
Wang, all of NIAID; Dr. Yaniv Lustig, Dr. Yael
[[Page 21509]]
Ottolenghi, and Dr. Dror Harats, all of Sheba Medical Center.
Publications: n/a.
Intellectual Property: HHS Reference No. E-200-2024-0. U.S.
Provisional Patent Application filed on July 31, 2024, and PCT Patent
Application No. PCT/US2025/039922, filed on July 30, 2025.
Licensing Contact: To license this technology, please contact Brian
Bailey at 240-669-5128, or <a href="/cdn-cgi/l/email-protection#caa8a8aba3a6afb38aa7aba3a6e4a4a3a2e4ada5bc"><span class="__cf_email__" data-cfemail="10727271797c7569507d71797c3e7e79783e777f66">[email protected]</span></a>, and reference E-200-
2024-0.
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize this technology. For collaboration
opportunities, please contact Brian Bailey at 240-669-5128, or
<a href="/cdn-cgi/l/email-protection#086a6a6961646d71486569616426666160266f677e"><span class="__cf_email__" data-cfemail="335151525a5f564a735e525a5f1d5d5a5b1d545c45">[email protected]</span></a>.
Dated: April 17, 2026.
Surekha Vathyam,
Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2026-07769 Filed 4-21-26; 8:45 am]
BILLING CODE 4167-05-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on April 22, 2026.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.